U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07764627) titled 'Study of SG301 for Renal AMR After Transplantation' on Aug. 10.
Brief Summary: To evaluate the safety and tolerability of SG301 injection in patients with antibody-mediated rejection (AMR) after renal transplantation.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Antibody Mediated Rejection
Intervention:
DRUG: SG301 Injection
Dosage form: solution for infusion; Route of administration: intravenous; Frequency: weekly intervals (QW) for 4 weeks, then every 4 weeks (Q4W) for 48 weeks.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Disclaimer: Curated by HT Syndication....